Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chinese Patent Office
Fuji
Teva
Cantor Fitzgerald
Medtronic

Generated: September 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,582,391

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,582,391
Title: Hybrid matrix implants and explants
Abstract:An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; and (b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.
Inventor(s): Mineau-Hanschke; Rochelle (Waltham, MA)
Assignee: Transkaryotic Therapies, Inc. (Cambridge, MA)
Application Number:10/188,628
Patent Claims:1. An extracorporeal apparatus comprising: a composition comprising a body of matrix material comprising insoluble collagen fibrils, there being embedded within the body of matrix material (a) a plurality of cultured vertebrate cells and (b) a plurality of microspheres; and a means for shunting blood from an animal to the composition and then back into a blood vessel of the animal.

2. The apparatus of claim 1, wherein the cultured vertebrate cells express and secrete a medically useful polypeptide.

3. The apparatus of claim 2, wherein the cultured vertebrate cells are genetically engineered to express the medically useful peptide.

4. The apparatus of claim 1, wherein the cultured vertebrate cells are selected from the group consisting of adipocytes, astrocytes, cardiac muscle cells, chondrocytes, endothelial cells, epithelial cells, fibroblasts, gangliocytes, glandular cells, glial cells, hematopoietic cells, hepatocytes, keratinocytes, myoblasts, neural cells, osteoblasts, pancreatic beta cells, renal cells, smooth muscle cells, striated muscle cells, and precursors of any of the above.

5. The apparatus of claim 1, wherein the cultured vertebrate cells are human cells.

6. The apparatus of claim 3, wherein the cultured vertebrate cells are transfected cells containing exogenous DNA encoding the polypeptide.

7. The apparatus of claim 3, wherein the cultured vertebrate cells are transfected cells containing exogenous DNA which includes a regulatory sequence that activates expression of a gene encoding the polypeptide, said gene being endogenous to said vertebrate cells both prior to and after they are transfected.

8. The apparatus of claim 2, wherein the polypeptide is selected from the group consisting of enzymes, hormones, cytokines, colony stimulating factors, vaccine antigens, antibodies, clotting factors, regulatory proteins, transcription factors, receptors, and structural proteins.

9. The apparatus of claim 2, wherein the polypeptide is an angiogenesis factor.

10. The apparatus of claim 2, wherein the polypeptide is selected from the group consisting of human growth hormone, Factor VIII, Factor IX, erythropoietin, and insulin.

11. The apparatus of claim 3, wherein the polypeptide is selected from the group consisting of human growth hormone, Factor VIII, Factor IX, erythropoietin, and insulin.

12. The apparatus of claim 2, wherein the cultured vertebrate cells secrete a polypeptide selected from the group consisting of alpha-1 antitrypsin, calcitonin, glucocerebrosidase, low density lipoprotein (LDL) receptor, IL-2 receptor, globin, immunoglobulin, catalytic antibodies, the interleukins, insulin-like growth factor 1 (IGF-1), parathyroid hormone (PTH), leptin, the interferons, the nerve growth factors, basic fibroblast growth factor (bFGF), acidic FGF (aFGF), epidermal growth factor (EGF), endothelial cell growth factor, platelet derived growth factor (PDGF), transforming growth factors, endothelial cell stimulating angiogenesis factor (ESAF), angiogenin, tissue plasminogen activator (t-PA), granulocyte colony stimulating factor (G-CSF), and granulocyte-macrophage colony stimulating factor (GM-CSF).

13. The apparatus of claim 1, wherein the microspheres are beads of type I collagen.

14. The apparatus of claim 1, wherein the matrix material additionally comprises a substance selected from the group consisting of a second type of collagen, agarose, alginate, fibronectin, laminin, hyaluronic acid, heparan sulfate, dermatan sulfate, sulfated proteoglycans, fibrin, elastin, and tenascin.

15. The apparatus of claim 1, wherein noncollagen fibers are dispersed within the body of matrix material.

16. The apparatus of claim 15, wherein the noncollagen fibers comprise a material selected from the group consisting of nylon, dacron, polytetrafluoroethylene, polyglycolic acid, polylactic/polyglycolic acid mixture, polystyrene, polyvinylchloride copolymer, cat gut, cotton, linen, polyester and silk.

17. The apparatus of claim 1, wherein each of the plurality of microspheres consists primarily of one or more substances selected from the list consisting of collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, and glass.

18. The apparatus of claim 1, wherein the microspheres have a diameter between approximately 0.1 and approximately 2 mm.

19. The apparatus of claim 1, wherein the collagen in the matrix material is type I collagen.

20. A method of administering a polypeptide to a patient in need thereof, comprising providing the extracorporeal apparatus of claim 2; and shunting a portion of the patient's blood through the apparatus and back into the patient's bloodstream, so that the polypeptide secreted by the cells mixes with the blood.

Details for Patent 6,582,391

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Try a Free Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2015-10-25 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Try a Free Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2015-10-25 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Try a Free Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2015-10-25 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Try a Free Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2015-10-25 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
UBS
Mallinckrodt
Medtronic
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.